BACKGROUND: Generally, the blood-brain barrier (BBB) of brain metastasis was thought to be disrupted. METHODS: We retrospectively performed immunohistochemical staining for glucose transporter 1 (GLUT1) and breast cancer resistance protein (BCRP) to evaluate the status of the BBB in resected brain metastases. Associations between expression of GLUT1 and/or BCRP and the immunohistochemical profiles of breast cancers, such as the statuses of hormone receptors, human epidermal growth factor receptor 2 (HER2/neu), and a basal-type marker (cytokeratin 5/6, HER1), were also analyzed. RESULTS: The study included 29 breast cancer patients with brain metastasis who had undergone brain tumor resections. Among the 29 patients, there was no expression of GLUT1 and BCRP in the intratumor microvessels of 9 (32%) and 11 (38%) patients, respectively. There was no expression of both GLUT1 and BCRP in 8 patients (28%). The expression of GLUT1 was significantly associated with that of BCRP (P < .001). A positive correlation was observed between the expression of GLUT1 and/or BCRP and brain metastases of HER2/neu-positive breast cancer (P = .012), while a negative correlation was observed between the expression of GLUT1 and/or BCRP and brain metastases of triple negative or basal-type breast cancer (P = .014 and P = .003 for triple negative and basal-type, respectively). CONCLUSIONS: Brain metastases of triple negative or basal-type breast cancers may often disrupt the BBB, whereas brain metastases of HER2/neu-positive breast cancer tend to preserve the BBB.
BACKGROUND: Generally, the blood-brain barrier (BBB) of brain metastasis was thought to be disrupted. METHODS: We retrospectively performed immunohistochemical staining for glucose transporter 1 (GLUT1) and breast cancer resistance protein (BCRP) to evaluate the status of the BBB in resected brain metastases. Associations between expression of GLUT1 and/or BCRP and the immunohistochemical profiles of breast cancers, such as the statuses of hormone receptors, humanepidermal growth factor receptor 2 (HER2/neu), and a basal-type marker (cytokeratin 5/6, HER1), were also analyzed. RESULTS: The study included 29 breast cancerpatients with brain metastasis who had undergone brain tumor resections. Among the 29 patients, there was no expression of GLUT1 and BCRP in the intratumor microvessels of 9 (32%) and 11 (38%) patients, respectively. There was no expression of both GLUT1 and BCRP in 8 patients (28%). The expression of GLUT1 was significantly associated with that of BCRP (P < .001). A positive correlation was observed between the expression of GLUT1 and/or BCRP and brain metastases of HER2/neu-positive breast cancer (P = .012), while a negative correlation was observed between the expression of GLUT1 and/or BCRP and brain metastases of triple negative or basal-type breast cancer (P = .014 and P = .003 for triple negative and basal-type, respectively). CONCLUSIONS:Brain metastases of triple negative or basal-type breast cancers may often disrupt the BBB, whereas brain metastases of HER2/neu-positive breast cancer tend to preserve the BBB.
Authors: B Milojkovic Kerklaan; O van Tellingen; A D R Huitema; J H Beijnen; W Boogerd; J H M Schellens; D Brandsma Journal: J Neurol Date: 2015-10-17 Impact factor: 4.849
Authors: Aurelija Jucaite; Per Stenkrona; Zsolt Cselényi; Serena De Vita; Nuria Buil-Bruna; Katarina Varnäs; Alicia Savage; Andrea Varrone; Peter Johnström; Magnus Schou; Chris Davison; Andy Sykes; Venkatesh Pilla Reddy; Matthias Hoch; Ana Vazquez-Romero; Mohammad Mahdi Moein; Christer Halldin; Melinda S Merchant; Martin Pass; Lars Farde Journal: Neuro Oncol Date: 2021-04-12 Impact factor: 12.300